

Product datasheet for **TL309444**

SIGLEC8 Human shRNA Plasmid Kit (Locus ID 27181)

Product data:

| | |
|----------------------------------|--|
| Product Type: | shRNA Plasmids |
| Product Name: | SIGLEC8 Human shRNA Plasmid Kit (Locus ID 27181) |
| Locus ID: | 27181 |
| Synonyms: | SAF2; SIGLEC-8; SIGLEC8L |
| Vector: | pGFP-C-shLenti (TR30023) |
| E. coli Selection: | Chloramphenicol (34 ug/ml) |
| Mammalian Cell Selection: | Puromycin |
| Format: | Lentiviral plasmids |
| Components: | SIGLEC8 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 27181). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
| RefSeq: | BC053319 , NM_014442 , NM_014442.1 , NM_014442.2 , NM_001363548 |
| UniProt ID: | Q9NYZ4 |
| Summary: | Sialic acid-binding immunoglobulin (Ig)-like lectins, or SIGLECs (e.g., CD33 (MIM 159590)), are a family of type 1 transmembrane proteins each having a unique expression pattern, mostly in hemopoietic cells. SIGLEC8 is a member of the CD33-like subgroup of SIGLECs, which are localized to 19q13.3-q13.4 and have 2 conserved cytoplasmic tyrosine-based motifs: an immunoreceptor tyrosine-based inhibitory motif, or ITIM (see MIM 604964), and a motif homologous to one identified in signaling lymphocyte activation molecule (SLAM; MIM 603492) that mediates an association with SLAM-associated protein (SAP; MIM 300490) (summarized by Foussias et al., 2000 [PubMed 11095983]).[supplied by OMIM, May 2010] |
| shRNA Design: | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service . |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).